ArticleDiscover oncology2026
Identification of prognostic signatures in pheochromocytomas and paragangliomas based on mitochondrial autophagy and ferroptosis in TCGA and GEO datasets.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas (PCCs) and paragangliomas (PGLs), collectively PPGLs, are rare tumors with significant molecular heterogeneity, which complicates prognosis and treatment. This study analyzed publicly available datasets (TCGA-PPGLs, GSE19422, GSE60459) to identify differentially expressed genes (DEGs) related to mitochondrial autophagy and ferroptosis in PPGLs. We identified 6,286 DEGs, including 31 mitochondrial ferroptosis-related DEGs (MFRDEGs). A prognostic model based on four genes (AMBRA1, EIF2S1, SRC, PHGDH) demonstrated high predictive accuracy (AUC > 0.9). Functional enrichment analysis highlighted key pathways, including mitophagy and Fc epsilon receptor I (FcεRI) signaling. Protein-protein interaction (PPI) and ceRNA network analyses revealed potential regulatory mechanisms. Calibration and decision curve analyses confirmed the model's clinical utility. These findings offer insights into PPGL molecular mechanisms, suggest prognostic biomarkers, and propose candidate therapeutic targets to improve risk stratification and personalized treatment. However, experimental validation is required to confirm their biological relevance before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.